What defines bioequivalence and what are typical acceptance criteria?

• A. Two formulations are bioequivalent if their rate and extent of absorption are similar; typical criterion: 90% CI for Cmax and AUC ratios within 0.8–1.25
• B. Two formulations must have identical Cmax values
• C. They must have identical AUC values
• D. They must have similar Tmax within a 2-hour window

Answer: (A)

Bioequivalence means two drug formulations deliver the same amount of drug into the bloodstream and do so at a similar rate, producing comparable overall exposure. Regulators focus on two key measures from concentration–time profiles: the rate of absorption, reflected by Cmax (the peak concentration), and the extent of absorption, reflected by AUC (the area under the concentration–time curve).

The standard acceptance criteria require that the 90% confidence intervals for the ratio of the test to reference products, for both Cmax and AUC, fall within 0.8 to 1.25. Data are usually log-transformed before this analysis to handle skewness, and then the results are back-transformed to give the ratio and its confidence interval. If both ratios’ confidence intervals lie entirely within 0.8–1.25, the two formulations are declared bioequivalent. This window allows a small, clinically acceptable degree of variability while ensuring similar exposure.

Why not insist on identical Cmax or identical AUC? Real-world variability means exact equality is unrealistic; a permissible 20% difference in either rate or extent is considered acceptable if the overall exposure stays within the specified range. Tmax, while informative about when peak levels occur, is more variable and not part of the formal regulatory criteria for bioequivalence, so similar Tmax alone does not define bioequivalence.